Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qualitek LabsBOM:544091 -0.69%46 Return-on-Tangible-Equity is 29.45% as of Mar. 2026, which is 26% above its 10-year median of 23.35. GuruFocus rates BOM:544091 with a GF Score™ of 46/100. The stock has 5 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Qualitek Labs ranks better than 76.96% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Qualitek Labs's annualized net income for the quarter that ended in Mar. 2026 was ₹197 Mil. Qualitek Labs's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹668 Mil. Therefore, Qualitek Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 29.45%.
The historical rank and industry rank for Qualitek Labs's Return-on-Tangible-Equity or its related term are showing as below:
BOM:544091'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 14.66 Med: 23.35 Max: 246.22
Current: 23.42
During the past 6 years, Qualitek Labs's highest Return-on-Tangible-Equity was 246.22%. The lowest was 14.66%. And the median was 23.35%.
BOM:544091's Return-on-Tangible-Equity is ranked better than 76.96% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.33
vs BOM:544091: 23.42
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Qualitek Labs Return-on-Tangible-Equity Related Terms
Qualitek Labs Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Qualitek Labs's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544091 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Qualitek Labs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qualitek Labs Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qualitek Labs's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Qualitek Labs's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 29.45% mean?
Qualitek Labs (BOM:544091) has a Return-on-Tangible-Equity of 29.45% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qualitek Labs and its competitors. This is 26% above median its historical median of 23.35. Over the past decade, Qualitek Labs' Return-on-Tangible-Equity has ranged from 14.66 to 246.22. According to the industry distribution chart, Qualitek Labs ranks #44 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 23%.
Is Qualitek Labs' Return-on-Tangible-Equity too high?
Qualitek Labs' current Return-on-Tangible-Equity of 29.45% is 26% above median its 10-year median of 23.35. Over the past 10 years, this metric has ranged from a low of 14.66 to a high of 246.22. Based on the distribution chart, Qualitek Labs ranks #44 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Qualitek Labs has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Qualitek Labs' Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Qualitek Labs ranks #44 out of 191 companies for Return-on-Tangible-Equity. This places Qualitek Labs in the top 23% of its industry — outperforming the majority of peers. Historically, Qualitek Labs' own Return-on-Tangible-Equity has ranged from 14.66 to 246.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qualitek Labs and its competitors. Qualitek Labs's current Return-on-Tangible-Equity is 29.45%, which is 26% above median its own 10-year median of 23.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qualitek Labs stock overvalued right now?
Qualitek Labs (BOM:544091) has a current Return-on-Tangible-Equity of 29.45%. The current Return-on-Tangible-Equity is 29.45%, which is 26% above median its 10-year median of 23.35. Qualitek Labs' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Qualitek Labs (BOM:544091), the current Return-on-Tangible-Equity is 29.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qualitek Labs Ltd is engaged in the business of providing testing, inspection, homologation, certification, and consultancy services to various industries such as automotive, defence, metals & metallurgy, environment and water, minerals, food & agriculture, pharma & healthcare.
46GF Score
Get the complete analysis for BOM:544091
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544091 has been successfully added to your 
